DOK家族在急性髓系白血病中的预后作用

Prognostic Role of the DOK Family in Acute Myeloid Leukemia

摘要: 急性髓系白血病是一种异质性恶性血液学系统，其特征是骨髓和外周血中的白血病细胞浸润，其发病率和相关死亡率迅速增加，在过去的30年中几乎翻了一番。估计2年和5年总生存率分别为32.0%和24.0%，明显低于其他白血病亚型。主要驱动突变，共发突变和复杂的基因–基因交互作用是白血病异质性原因，并影响患者生活质量。基因突变和表达谱可以帮助识别不同的预后亚组。然而，关于预后的标准指南缺乏共识，随着测序技术和生物信息学资源的发展，迫切需要发现和评估新的标记物，为诊断评估、生存预测和治疗方案提供可靠的临床指导。酪氨酸激酶(DOK)蛋白的下游是一个多基因的衔接子家族；其中一些是免疫细胞信号传导的关键负调节剂。然而，DOK家族在AML中的表达和临床意义很少被研究。

Abstract: Acute myeloid leukemia is a heterogeneous hematologic malignancy characterized by infiltration of leukemia cells in bone marrow and peripheral blood, with rapidly increasing morbidity and associ-ated mortality, which has nearly doubled over the past 30 years. The estimated 2-year and 5-year overall survival rates were 32.0% and 24.0%, respectively, significantly lower than those of other leukemia subtypes. Major driver mutations, co-occurring mutations, and complex gene-gene inter-actions contribute to leukemic heterogeneity and affect patient quality of life. Gene mutations and expression profiles can help identify different prognostic subgroups. However, there is a lack of consensus on standard guidelines for prognosis, and with the development of sequencing technolo-gy and bioinformatics resources, there is an urgent need to discover and evaluate new markers to provide reliable clinical guidance for diagnostic assessment, survival prediction, and treatment op-tions. The downstream tyrosine kinase (DOK) protein is a multigene bridging subfamily; some of them are key negative regulators of immune cell signaling. However, the expression and clinical significance of the DOK family in AML have rarely been studied.